Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Juan García-Bernalt Diego *Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-6947-6806
Javier Arranz-Herrero *Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-4107-2460
Gabriel LaghlaliDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Eleanor BurgessDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Seok-Chan ParkDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Gagandeep SinghDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Lauren A ChangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-3287-3987
Prajakta WarangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Moataz NoureddineDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jordi OchandoNational Microbiology Center, National Institutes of Health Carlos III, Madrid, Spain.ORCID 0000-0001-7037-1681
Estanislao Nistal-VillanMicrobiology Section, Dpto. CC, Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.ORCID 0000-0003-2458-8833
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-3156-3132
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Translational Immunology Training ProgramT32AI078892 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Karen Leigh Edelblum, SERGIO A. LIRA · 2008 to 2026
$4.5M
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunityR21AI176069 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2023 to 2024
$466k
A Miniature Pig Model for the Study of Host-Immune Responses Against Influenza A VirusR21AI151229 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RICHT, JUERGEN A, SCHOTSAERT, MICHAEL · 2020 to 2021
Secondary bacterial infections can significantly worsen the clinical course of influenza virus infections and are a leading cause of morbidity and mortality during seasonal influenza epidemics. Despite being a vaccine-preventable disease, influenza-related complications from secondary bacterial infections are an important cause of death, particularly among the elderly population. IMPORTANCE: In this study, we show that a licensed influenza vaccine not only prevents severe disease upon influenza virus infection but also helps protect against enhanced morbidity due to co- or superinfection with S
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice. · full record | Socratic